Early clinical trials have indicated that PD-L1 expression on tumor-infiltrating lymphocytes and tumor cells may increase the response to PD-1-directed therapies in metastatic NSCLC (Herbst et al., 2014, 2016; Ramalingam et al., 2016). The gene discussed is CD274; the disease is neoplasm.